A bacteria-based system expressing anti-TNF-α nanobody for enhanced cancer immunotherapy
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics
Link
https://www.nature.com/articles/s41392-023-01364-0.pdf
Reference9 articles.
1. Segaert, S. et al. Clinical signs, pathophysiology and management of cutaneous side effects of anti-tumor necrosis factor agents. Am. J. Clin. Dermatol 18, 771–787 (2017).
2. Harrison, M. L. et al. Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. J. Clin. Oncol. 25, 4542–4549 (2007).
3. Madhusudan, S. et al. Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer. J. Clin. Oncol. 23, 5950–5959 (2005).
4. Paik, P. K. et al. Phase I trial of the TNF-alpha inhibitor certolizumab plus chemotherapy in stage IV lung adenocarcinomas. Nat. Commun. 13, 1–8 (2022).
5. Liang, K. et al. Genetically engineered Salmonella typhimurium: recent advances in cancer therapy. Cancer Lett. 448, 168–181 (2019).
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Next-Generation Therapeutic Antibodies for Cancer Treatment: Advancements, Applications, and Challenges;Molecular Biotechnology;2024-09-02
2. Engineered bacteria breach tumor physical barriers to enhance radio-immunotherapy;Journal of Controlled Release;2024-09
3. Targeting cytokine and chemokine signaling pathways for cancer therapy;Signal Transduction and Targeted Therapy;2024-07-22
4. Development of a bacteria-nanosapper for the active delivery of ZIF-8 particles containing therapeutic genes for cancer immune therapy;Acta Pharmaceutica Sinica B;2024-07
5. Expanded ROS Generation and Hypoxia Reversal: Excipient‐free Self‐assembled Nanotheranostics for Enhanced Cancer Photodynamic Immunotherapy;Advanced Materials;2024-05-20
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3